|
| |
| |
|
|
|
2004 News Releases
- Nov 15, 2004 - Wex Initiates Phase IIa Clinical Trial of Tetrodin™ for Reduction of Withdrawal Symptoms in Opiate Dependent Patients
- Nov 09, 2004 - International Wex Reports Financial Results for Second Quarter Ended September 30, 2004 (pdf doc.)
- Oct 25, 2004 - International
Wex Technologies Inc. changes name to Wex Pharmaceutucals Inc.
- Sep 24, 2004 - Wex Amends Financial
Disclosure for the First Quarter Ended June 30, 2004
- Sep 23, 2004 - Wex Announces
Tectin™ Phase IIa Final Results Presented Today at the 3rd.
World Congress World Institute of Pain
- Aug 26, 2004 - Wex Announces
Clinical Study for Tetrodin™/Reports on Progress with U.S.
Pain Program
- Aug 17, 2004 - International
Wex Reports Financial Results for First Quarter Ended June 30,
2004
- Aug 16, 2004 - International
Wex Reports Results for the Fiscal Year Ended March 31, 2004
- Jul 28, 2004 - Tectin™
Phase II Trial Begins in China
- Jul 09, 2004 - Newly Appointed
CFO
- Jun 15, 2004 - US$5.1 Million
Convertible Debentures Closed
- Jun 08, 2004 - Manufacturing
and Option Agreement Remains Unchanged
- May 17, 2004 - US$5.1 Million
Convertible Debenture
- May 07, 2004 - International
Wex Technologies' Tectin™ Study Results Show Efficacy in
Pain Management
- May 05, 2004 - Pivotal Phase IIb/III
Trial of Tectin™ for Cancer Pain Begins
- Apr 13, 2004 - Regulatory Approval
for an Open Label Clinical Trial
- Apr 12, 2004 - Recent Market
Activity
- Apr 01, 2004 - Open Label Application
Filed / Trial Progress
- Mar 30, 2004 - Pain Management
Portfolio Expanded - First Drug License Obtained in Canada
- Mar 29, 2004 - Peru Grants Authorization
- Mar 25, 2004 - Change of Auditor
- Mar 16, 2004 - Trademark registration
granted
- Mar 15, 2004 - International
Wex and Sabex conclude agreement
- Mar 10, 2004 - WEX begins trading
on Toronto Stock Exchange
- Mar 09, 2004 - Trading on the
Toronto Stock Exchange Commences
- Feb 25, 2004 - Conditional listing
approval of the Toronto Stock Exchange
- Feb 23, 2004 - Appointment of
C.F.O. & Vice-President, Corporate Communications
- Feb 19, 2004 - Phase II Clinical
Trial for Tectin™ approved in China
- Jan 30, 2004 - Final closing
on $10,000,000 Financing Including a fully subscribed overallotment
of $4,000,000
- Jan 8, 2004 - Pivotal Phase IIb/III
Clinical Trial for Tectin™ cleared to start
immediately
< 2003 news :: 2005 news >
|
 |
|
|
|
| Home | News | Corporate | Products | Clinical Trials | Investors | Licensing | Contact | |
|
Copyright WEX Pharmaceuticals Inc. All rights reserved.
Privacy Policy | Disclaimer
Website designed by Attention Media.
|
|
